Does the recent Aprea Therapeutics Form 4 show any insider share sales by Rifat Pamukcu?

The Form 4 shows only acquisition-type transactions for Pamukcu: grants of restricted stock units and stock options. There are no reported open-market purchases or sales, and no disposal transactions, in this particular filing’s transaction summary.

Aprea Therapeutics (APRE) director receives new RSUs, options and updates holdings

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aprea Therapeutics director Rifat Pamukcu reported new equity awards and updated holdings. On June 16, 2026, he received 3,135 restricted stock units that will vest and settle in common stock on June 16, 2027, subject to his continued board service and possible acceleration under certain conditions.

He was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, vesting in full on June 16, 2027 under similar service-based conditions. Following these awards, he directly holds 8,581 common shares and 12,555 options, and indirectly holds 14,108 common shares through ZNZ Holdings LLC, where he serves as Manager Partner.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Pamukcu Rifat

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	12,555	$0.00	--
Grant/Award	Common Stock	3,135	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 12,555 shares (Direct, null); Common Stock — 8,581 shares (Direct, null); Common Stock — 14,108 shares (Indirect, By ZNZ Holdings LLC)

Footnotes (1)

These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. The Reporting Person serves as Manager Partner of ZNZ Holdings L.L.C. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Key Figures

Restricted stock units granted: 3,135 units Stock options granted: 12,555 options Option exercise price: $0.7293 per share +3 more

6 metrics

Restricted stock units granted 3,135 units Granted on June 16, 2026; vest June 16, 2027

Stock options granted 12,555 options Granted on June 16, 2026; expire June 16, 2036

Option exercise price $0.7293 per share Stock options on common stock

Direct common shares after awards 8,581 shares Total direct holdings following transactions

Indirect common shares via ZNZ Holdings 14,108 shares Indirect holdings reported as by ZNZ Holdings LLC

Option expiration date June 16, 2036 Expiration of 12,555 granted stock options

Key Terms

restricted stock units, Stock Options (Right to Buy), indirect ownership, Grant, award, or other acquisition, +1 more

5 terms

restricted stock units financial

"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) with 12,555.0000 shares and an exercise price of 0.7293"

indirect ownership financial

"total_shares_following_transaction 14108.0000 with ownership_type indirect and nature_of_ownership By ZNZ Holdings LLC"

Grant, award, or other acquisition financial

"transaction_code_description Grant, award, or other acquisition for the common stock and option grants"

vesting financial

"which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/17/2026 - 07:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pamukcu Rifat

(Last)

(First)

(Middle)

3805 OLD EASTON ROAD

(Street)

DOYLESTOWN

PENNSYLVANIA

18902

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aprea Therapeutics, Inc. [ APRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2026		A		3,135⁽¹⁾	A	$0.00	8,581	D
Common Stock								14,108	I	By ZNZ Holdings LLC⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$0.7293	06/16/2026		A		12,555		⁽³⁾	06/16/2036	Common Stock	12,555	$0.00	12,555	D

Explanation of Responses:

1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

2. The Reporting Person serves as Manager Partner of ZNZ Holdings L.L.C.

3. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

	/s/ John Hamill, as Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Aprea Therapeutics (APRE) director Rifat Pamukcu receive?

Rifat Pamukcu received 3,135 restricted stock units and stock options for 12,555 shares. Both awards were granted on June 16, 2026 and are tied to his continued service on Aprea Therapeutics’ board, with vesting dates in June 2027.

When do the new Aprea Therapeutics (APRE) RSUs for Rifat Pamukcu vest?

The 3,135 restricted stock units vest and settle in common stock on June 16, 2027. Vesting requires Pamukcu’s continued service on Aprea Therapeutics’ board through that date and may accelerate under certain specified conditions in the award terms.

What are the key terms of Rifat Pamukcu’s new Aprea Therapeutics stock options?

Pamukcu’s new options cover 12,555 shares of common stock at an exercise price of $0.7293 per share. The options vest in full on June 16, 2027, conditioned on his continued board service and subject to potential acceleration provisions.

How many Aprea Therapeutics (APRE) shares does Rifat Pamukcu hold directly and indirectly?

After these awards, Pamukcu directly owns 8,581 shares of Aprea Therapeutics common stock. He also indirectly holds 14,108 shares through ZNZ Holdings LLC, an entity for which he serves as Manager Partner, according to the Form 4 disclosure.

What is the nature of Rifat Pamukcu’s indirect ownership in Aprea Therapeutics?

Pamukcu’s indirect ownership consists of 14,108 Aprea Therapeutics common shares held by ZNZ Holdings LLC. The filing notes he serves as Manager Partner of ZNZ Holdings, indicating these shares are held through that entity rather than in his personal name.